April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
3 citations
,
January 2010 in “Yearbook of Urology” January 2010 in “Yearbook of Urology”
October 2025 in “Open Repository of the University of Porto (University of Porto)” Dutasteride is more effective than finasteride for hair growth, and sublingual apomorphine quickly improves Parkinson's symptoms.
1 citations
,
February 2025 in “Pediatric Dermatology” Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.
44 citations
,
October 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
January 2017 in “Más dermatología” Topical finasteride may help treat hair loss in men and women.
December 2015 in “PLOS ONE” 20 citations
,
January 2004 in “PubMed” Dutasteride reduces DHT more than finasteride, but both drugs improve BPH symptoms similarly.
January 2024 in “Dermatologic therapy” Tofacitinib is a safe treatment for hair loss in children, but long-term use may be needed for best results.
2 citations
,
September 2001 in “PubMed” Finasteride is advertised directly to consumers for treating male pattern hair loss.
October 2015 in “Elsevier eBooks” Finasteride helps hair growth and prostate issues but may cause sexual side effects and increase tumor risk.
January 2024 in “Dermatologic Therapy” Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
Three reliable methods were developed to measure Finasteride and Tamsulosin Hydrochloride in medicines.
7 citations
,
March 2021 in “Journal of the American Academy of Dermatology” Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.
2 citations
,
January 2023 in “Anais Brasileiros de Dermatologia”
September 2025 in “International Journal of Innovative Technologies in Social Science” Dutasteride is more effective than finasteride for hair loss, but more research is needed on safety and dosing.
Teprotumumab for thyroid eye disease commonly causes fatigue, brittle nails, dry eyes, hair loss, muscle spasms, and dry mouth, with rare serious events like blood clots.
3 citations
,
May 2023 in “International Journal of Molecular Sciences” A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.
January 2023 in “National Journal of Physiology, Pharmacy and Pharmacology” Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
September 2017 in “Hair transplant forum international”
June 2017 in “Journal of The American Academy of Dermatology” Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.
September 2024 in “Health of Man” Low-dose dutasteride effectively and safely promotes hair growth in men with androgenetic alopecia.
May 2024 in “Reactions weekly”
March 2020 in “Section 5: Patient safety and quality assurance” Tofacitinib and baricitinib had an acceptable level of side effects in rheumatoid arthritis patients.
4 citations
,
March 2019 in “Acta Chromatographica” Two methods can measure finasteride and tamsulosin hydrochloride; HPLC is more advantageous, while TLC offers better separation.
1 citations
,
November 2021 in “British Journal of Clinical Pharmacology” Saw palmetto may cause erectile dysfunction and needs better safety monitoring.
October 2010 in “Journal of Men's Health” The conclusion is that doctors should be careful when prescribing 5α-reductase inhibitors due to possible serious side effects, and they should discuss these risks with patients.